Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond

References

• Burkhardt R, Bard R, Jaeger K, Frisch B, Ketmer G, Mahl G, Sund M. Chronic myeloproliferative disorders. Path Res Pract 1084179:131–186.
   Google Scholar
• Georgii A, Vykuopli KF, Thiele J. Chronic megakaryocytic granulocytic myelosis: CMGM. Virch Arch A Path Anat Histol 1980;389:253–268.
   PubMed Web of Science ®Google Scholar
• Georgii A, Vykoupil KF, Buhr Th, Choritz H, Doehler U, Kaloutsi V, Werner M. Chronic myeloproliferative disorders in bone marrow biopsies. Path Res Pract 1990;186:3–27.
   PubMed Web of Science ®Google Scholar
• Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leukemia and Lymphoma 1996;22:15–29.
   PubMed Web of Science ®Google Scholar
• Thiele J, Ballard AC, Georgii A, Vykoupil KF. Chronic megakaryocytic granulocytic myelosis: An electron micro-scopic study, Megakaryocytes and thrombocytes. Virch Arch (Path Anat Histol) 1977;373:191–211.
   Google Scholar
• Thiele J, Holgado S, Choritz H, Georgii A. Density distribu-tion and size of megakaryocytes in inflammatory reactions of the bone marrow (myelitis) and chronic myeloproliferative disorders. Scand J Haematol 1983;31:329–341.
   Google Scholar
• Thiele J, Zankovich R, Schneider G, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus poly-cythemia vera rubra. A histomorphometric analysis of bone marrow features in trephine biopsies. Analyt Quat Cytol Histol 1988;10:375–382.
   PubMed Web of Science ®Google Scholar
• Thiele J, Zankovich R, Steinberg T, Kremer B, Fischer R, Diehl V. Primary (essential) thrombocythemia versus hyper-plastic stages of agnogenic myeloid metaplasia with thrombo-cytosis: a critical evaluation of clinical and histomorphological data. Acta Haematol 1989;81:192–202.
   PubMed Web of Science ®Google Scholar
• Thiele J, Wagner S, Degel C, et al. Megakaryocyte precursors (pro- and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. Virch Arch (Cell Pathol) 1990;58:295–302.
   Google Scholar
• Thiele J, Kvasnick HM, Werden C, Zankovich R, Diehl, Fischer R. Idiopathic primary osteo-myelofibrosis: A clinico-pathological study on 208 patients wit special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuke-mia and Lymphoma 1996;22:303–317.
   PubMed Web of Science ®Google Scholar
• Michiels JJ. The myeloproliferative disorders. An historical appraisal and personal experiences. Leukemia & Lymphoma 1997;22:1–14.
   Web of Science ®Google Scholar
• Michiels JJ. Diagnostic criteria of the myeloproliferative disorders (MPD) essential thrombocythemia, polycythemia vera and chronic megakaryocytic granulocytic metaplasia. Neth J Med 1997;51:57–64.
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb He-mostas 1997;23:339–347.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Fischer R. Histochemistry and morphometry on bone marrow biopsies in chronic myelopro-liferative disorders: aids to diagnosis and classification Ann Hematol 1999;78:495–506.
   Google Scholar
• Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disrders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leukemia & Lymphoma 1999;33: 207–218.
   Google Scholar
• WHO classification of the chronic myeloproliferative diseases (CMPD) polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia and CMPD unclassifiable. WHO Classification of Tumours. Tumours of Haematopoiesis and Lymphoid Tissues, Lyon. IARC 2001 pp 31–42.
   Google Scholar
• Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133–145.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Zankovich R, Diehl V. The value of bone marrow histopathology for the differentiation between early stage polycythemia vera and secondary (reactive) poly-cythemias. Haematologica 2001;86:368–374.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Muehlhausen K, Walter S, Zanko-vich R, Diehl V. Polycythemia rubra vera versus secondary polycythemias A clinicopathological evaluation of distinctive features in 199 patients. Pathology Res Pract 2001;197: 77–84.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Diehl V. Bone marrow features of diagnostic impact in erythrocytosis. Ann Heamatol 2005;84: 362–367.
   Google Scholar
• Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythe-mia. Acta Haematologica 2005;113:213–219.
   Google Scholar
• Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera PV. Histol Histpathol 2005;20:317–328.
   PubMed Web of Science ®Google Scholar
• Michiels JJ. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic myeloid metaplasia. Hematol J 2004;5:93–102.
   PubMedGoogle Scholar
• De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythrid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemos-tas 1997;23:411–418.
   PubMed Web of Science ®Google Scholar
• Briere BJH 2005.
   Google Scholar
• Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocythemia by novel, simple accurate clonality assays and comparison with PRV-1 expression and BFU:E response to erythropoietin. Blood 2003;101:3294–3301.
   PubMed Web of Science ®Google Scholar
• Shih L-Y, Lee C-T. Indentification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 1994;83:744–748.
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Ten Kate FJW. Erythromelalgia in thrombocythe-mia of various myeloproliferative disorders. Am J Hematol 1992;39:131–136.
   PubMed Web of Science ®Google Scholar
• Bauermeister DE. Quantitation of bone marrow reticulin. Am J Chin Pathol 1971;56:24–31.
   PubMed Web of Science ®Google Scholar
• Reilly JT. Pathogenesis of idiopathic myelofibrosis: present status and future directions. Br J Haematol 1994;88:1–8.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Silverstein MN, Noel P. Agnogenic myeloid metaplasia. Semin Hematol 1995;22:327–333.
   Google Scholar
• Barosi G, Ambrosetti A, Finelli, et al. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999;104:730–737.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. New Eng J Med 2000;342:1255–1265.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelogibrosis (IMF): a clinicopathological study. Leukemia 1999;13:1741–17428.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnika HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofi-brosis. Haematlogica 2000;85:1126–1134.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idipathic (primary) myelofibrosis. Ann Hematol 2001;80:160–165.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Early stage idiopathic (primary) myelofibrosis: current issues of diagnostic features. Leukemia & Lymphoma 2002;43:1036–1041.
   Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. Diagnostic differentiation of essen-tial thrombocythemia from thrombocythemia associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features: a clinicopathological study on 272 patients. Histol Histopathol 2003;18:93–102.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Dy-namics of fibrosis in chronic idiopathic (primary) myelofibro-sis during therapy: a follow-up on 308 patients. Leukemia and Lymphoma 2003;44: 949–953.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van Der Walt J, Orazi A. European consensus for grading of bone marrow fibrosis and assessment of cellularity in myeloproliferative disorders. Haematologica Hematol J 2005, in pressz.
   Google Scholar
• Michiels JJ, Kvasnicka HM, Thiele J. Myeloproliferative Disorders: current perspectives on diagnostic criteria, histo-pathology and treatment. 2005 ISBN 3-9898075-6-8 Verlag ME Uwe Grunwald, Munich Germany.
   Google Scholar
• Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classifica-tions systems (PVSG-WHO) on 839 patients. Ann Hematol 2003;82:148–152.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Diehl V. Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders: a clinicopathological study on 575 patients. Leukemia & Lymphoma 2005;46: 709–715.
   PubMed Web of Science ®Google Scholar
• Florena AM, Tripodi C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004;89:911–919.
   PubMed Web of Science ®Google Scholar
• Westwood NB, Pearson TC. Diagnostic applications of haematopoietic progenitor culture techniques in polycythae-mias and thrombocythaemias. Leukemia & Lymphoma 1996; 22:95–103.
   PubMed Web of Science ®Google Scholar
• Johanson P, Andreason B, Safai-Kutti S, Wennstrom L, Palmqvist L, Rickson A, Lindstedt G, Kutti J. The presence of a significant association between elevated PRV-1 mRNA expression and low plasma erythropoietin concentration in essential thrombocythemia. Eur J Haematol 2003;70: 358–362.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Klippel S, Strunk E, Temeric S, Mohr U, Heimpel H, Pahl HL. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol 2004; 83:364–370.
   Google Scholar
• Michiels JJ, Ten Kate FWJ, Vuzevski VD, Abels J. Histo-pathology of erythromelalgia in thrombocythemia. Histo-pathology 1984;8:669–678.
   Google Scholar
• Adamson JW, Fialkov PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N EngJ Med 1976;295:913–916.
   Google Scholar
• Fialkov PJ, Faquet GB, Jacobson RJ, Vaida K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916–919.
   Google Scholar
• El-Kassar N, Hetet G, Briere J, Grandschamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: ad-vantages of studying T lymphocytes and platelets. Blood 1997; 89:128–134.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Gale RE, Machin SJ. Linch DC, A large proportion of patients with the diagnosis of essential throm-bocythemia do not have a clonal disorder and may be at lower risk of thrombosis. Blood 1999;93:417–424.
   Google Scholar
• Shih LY, Lin TL, Lai CL, Dunn P, Wu JH, Wang PN, et al. Predictive value of X-chromosome inactivation patterns and clinicopathological parameters for vascular complications in female patients with essential thrombocythemia. Blood 2002; 100:1596–15601.
   PubMed Web of Science ®Google Scholar
• Prchal JF, Axelrad AE. Bone marrow responses in polycythe-mia vera. N Eng J Med 1974;290:1382 (Letter).
   PubMed Web of Science ®Google Scholar
• Dobo I, Donnard M, Girodon F, Mossuz P, Boiret N, Boukhari R, Allégraud A, Bascans E, Campos L, Pineau D, et al. Standardization and comparison of endogenous ery-throid colony assays performed with bone marrow and blood progenotors for the diagnosis of polycythemia vera. Hematol J 2001;2:396–403.
   Google Scholar
• Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1. Blood 1994;84: 99–112.
   Google Scholar
• Mirza AM, Correa PN, Axelrad AA. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor 1 receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. Blood 1995;86: 877–882.
   PubMed Web of Science ®Google Scholar
• Mirza AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood 1997;89: 1862–1869.
   PubMed Web of Science ®Google Scholar
• Juvonen E, Ikkala E, Oksanen K, Ruutu T. Megakaryocyte and erythroid colony formation in essential thrombocythemia and reactive thrombocytosis: diagnostic value and correlation to complications. Brit J Haematol 1993;83:192–197.
   PubMed Web of Science ®Google Scholar
• Florensa L, Bessis C, Woessner S, Sole F, Acin P, Pedro C, Sans-Sabrafen J. Endogenous megakaryocyte and erythroid colony formatio from blood in essential thrombocythemia. Leukemia 1995;9:271–273.
   Google Scholar
• Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Jormila P, Jansson SF, Kekomaki R, Ruutu T. Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings. Ann Hematol 1998;77:101–106.
   PubMed Web of Science ®Google Scholar
• Axelrad AA, Eskinazi D, Correa PN, Amata D. Hypersensi-tivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHU MGDF) in essential thrombocythemia. Blood 2000;96:3310–3321.
   PubMed Web of Science ®Google Scholar
• Axelrad AA, Eskinazi D, Amato D. Does hypersensitivity of progenitor cells to normal cytokine(s) play a role in the pathogenesis of idiopathic myelofibrosis with myeloid meta-plasia? Blood 1999;94:2866.
   Google Scholar
• Temerinac S, Klippel S, Strunck E, Roder S, Lübbert M, Lange M, Meinhardt G, Schaefer HE, Pahl HL. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000;95: 2569–2576.
   PubMed Web of Science ®Google Scholar
• Pahl HL. Towards a molecular understanding of polycythemia ribra vera. Eur J Biochem 2000;267:3395–3401.
   PubMedGoogle Scholar
• Klippel S, Strunck E, Termerinac S, et al. Quantification of PRV-1 expression, a molecular marker for the diagnosis of polycythemia vera. Blood 2001;98:470a.
   Web of Science ®Google Scholar
• Pahl HL. Molecular markers in MPDs. Proceedings First Como Workshop on the molecular pathogenesis and genetics of myeloproliferative disorders. 2002.
   Google Scholar
• James C, Ugo V, Le Couedic PF, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005; 434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Kaushanky K. On the origin of the chronic myeloproliferative disorders: it makes all sense. Blood 2005;105:4187–4190.
   PubMed Web of Science ®Google Scholar
• Goldman JM. A unifying mutation in chronic myeloprolifera-tive disorders. New Eng J Med 2005;352:1744–1745.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Skoda R. Gain of function, loss of control. A molecular basis for chronic myeloproliferative disorders. Haematologica Hematol J 2005;90:871–874.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer cells 2005;7:387–397.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Paasamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Eng J Med 2005352:1779-1790.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas-Swanton S, et al. Acquired mutation of the tyrosine kinase Jin human myeloproliferative disorders. Lancet 2005;365:1054–1061.
   Google Scholar
• Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz AS, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005.
   Google Scholar
• Jones AV, Kreil S, Xoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; May 26[Epub ahead of print].
   Web of Science ®Google Scholar
• Steensma DP, Dewald M, Lasho TL, Powell HL, McClure RF, Levine RL et al. TheJAK2 V617F activating tyrosine kinase mutation is an infrequent event in bothatypical myeloproliferative disorders and the myelodysplastic syn-drome. Blood 2005 28 [Epub ahead of print].
   Google Scholar
• Jelinek J, Oh Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMNIL, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 2005 [Epub ahead of print].
   PubMedGoogle Scholar
• Tefferi A, Gilliland DG. The JAK2 V617F tyrosine kinase mutation in myeoproliferative disorders: statu report and immedate implications for diesaesclassification and diagnosis. Mayo Clin Proc 2005;80:947–958.
   PubMed Web of Science ®Google Scholar